Aceto Corporation (ACET): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACET POWR Grades
- ACET scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.19% of US stocks.
- ACET's strongest trending metric is Stability; it's been moving down over the last 179 days.
- ACET ranks lowest in Momentum; there it ranks in the 4th percentile.
ACET Stock Summary
- Adicet Bio Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.58% of US listed stocks.
- With a price/sales ratio of 77.71, Adicet Bio Inc has a higher such ratio than 97.14% of stocks in our set.
- Revenue growth over the past 12 months for Adicet Bio Inc comes in at -45.65%, a number that bests only 3.54% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Adicet Bio Inc, a group of peers worth examining would be ONCT, SLDB, FDMT, CRBP, and CCCC.
- Visit ACET's SEC page to see the company's official filings. To visit the company's web site, go to www.restorbio.com.
ACET Valuation Summary
- In comparison to the median Healthcare stock, ACET's price/earnings ratio is 113.15% lower, now standing at -4.8.
- Over the past 44 months, ACET's price/sales ratio has gone NA NA.
- Over the past 44 months, ACET's EV/EBIT ratio has gone up 12.2.
Below are key valuation metrics over time for ACET.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACET | 2021-08-31 | 28.7 | 1.2 | -4.8 | -1.3 |
| ACET | 2021-08-30 | 27.5 | 1.1 | -4.6 | -1.1 |
| ACET | 2021-08-27 | 27.7 | 1.1 | -4.6 | -1.1 |
| ACET | 2021-08-26 | 26.4 | 1.1 | -4.4 | -0.9 |
| ACET | 2021-08-25 | 25.2 | 1.0 | -4.2 | -0.7 |
| ACET | 2021-08-24 | 25.0 | 1.0 | -4.1 | -0.7 |
ACET's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACET has a Quality Grade of D, ranking ahead of 8.53% of graded US stocks.
- ACET's asset turnover comes in at 0.043 -- ranking 330th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ACET's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.043 | 1 | -1.841 |
| 2021-03-31 | 0.027 | 1 | -2.369 |
| 2020-12-31 | 0.157 | 1 | -2.317 |
| 2020-09-30 | 0.031 | 1 | -3.142 |
| 2020-06-30 | 0.000 | NA | -1.790 |
| 2020-03-31 | 0.000 | NA | -1.243 |
ACET Price Target
For more insight on analysts targets of ACET, see our ACET price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $28.29 | Average Broker Recommendation | 1.21 (Strong Buy) |
ACET Stock Price Chart Interactive Chart >
ACET Price/Volume Stats
| Current price | $14.58 | 52-week high | $21.17 |
| Prev. close | $14.60 | 52-week low | $6.25 |
| Day low | $14.56 | Volume | 96,159 |
| Day high | $14.98 | Avg. volume | 482,224 |
| 50-day MA | $12.66 | Dividend yield | N/A |
| 200-day MA | $12.63 | Market Cap | 583.26M |
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover CandidateAdicet Bio (ACET) was founded in 2014 and is based in Boston, Massachusetts. The company’s platform is based on gamma delta T cells, which have been major investor attention recently. The first generation of CAR T therapies was based on alpha beta T cells and had issues with durability and... |
Analysts Are Bullish on These Healthcare Stocks: Adicet Bio (ACET), Marinus (MRNS)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACET – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments. Adicet Bio (ACET) H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $35.00. The company's shares closed last Thursday at $12.13. According to TipRanks. |
JMP Securities Remains a Buy on Adicet Bio (ACET)In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Adicet Bio (ACET – Research Report), with a price target of $30.00. The company's shares closed last Thursday at $12.30. According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -12.0% and a 31.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $32.00 average price target, a 158.1% upside from current levels. |
Adicet Bio to Participate in Guggenheim 2022 Oncology ConferenceMENLO PARK, Calif. & BOSTON, February 02, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022. |
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesMENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a pub |
ACET Price Returns
| 1-mo | 29.14% |
| 3-mo | -29.94% |
| 6-mo | -16.64% |
| 1-year | 50.31% |
| 3-year | -79.74% |
| 5-year | N/A |
| YTD | -16.64% |
| 2021 | 24.48% |
| 2020 | 34.71% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...